Weekly paclitaxel administration in the adjuvant therapy of primary breast cancer
Takahashi, H.; Takahashi, M.; Taguchi, K.; Sasaki, F.; Todo, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(5): 653-659
2003
ISSN/ISBN: 0385-0684 PMID: 12795097 Document Number: 559186
To investigate feasibility and toxicity of weekly paclitaxel administration in the adjuvant therapy of primary breast cancer. Thirty-one patients with primary breast cancer received sustained weekly infusion of paclitaxel at a dose of 90 mg/body for 6 weeks followed by a 2-week interval. This weekly schedule was repeated twice. Leukocytes were checked immediately before every infusion and the dose was reduced to 80 mg/body when grade 1 neutropenia occurred. All patients were assessable for feasibility and toxicity. A total 349 weekly paclitaxel infusions were administrated to 31 patients (median, 12 infusions/patient). The median delivered dose-intensity was 88.0 mg/body/week (range 80 to 90). Therapy was well tolerated and completed in 27 patients. Four patients refused to continue the therapy because of nausea, fatigue, dizziness and weight gain. Grade 2 neutropenia occurred in 10 patients (32.3%), but grade 3 neutropenia did not occur. Grade 1 peripheral neuropathy occurred in 3 patients (9.7%). Grade 1 nausea occurred in 3 patients (9.7%). Weekly paclitaxel administration is well tolerated with a favorable toxicity profile in patients with primary breast cancer in the adjuvant setting. Weekly paclitaxel therapy can be performed safely in the outpatient setting.